论文部分内容阅读
目的探讨百普素口服辅助治疗胎儿宫内发育受限(FGR)的安全性及临床效果。方法选取2013年1月~2014年12月在我院住院治疗FGR孕妇120例,随机分成治疗组和对照组,其中治疗组60例,对照组60例。治疗前后测宫高、腹围、胎儿双顶径及出生后新生儿的体重和胎盘重量。结果治疗组的各项指标均高于对照组,两组低体重儿发生率和早产儿早产率存在统计学差异明显,P<0.05。结论百普素治疗FGR效果显著。
Objective To investigate the safety and clinical efficacy of berberine in adjuvant treatment of fetal intrauterine growth restriction (FGR). Methods From January 2013 to December 2014, 120 pregnant women hospitalized with FGR in our hospital were randomly divided into treatment group and control group, including 60 in treatment group and 60 in control group. Measured before and after treatment of high uterine, abdominal circumference, fetal biparietal diameter and birth weight and placental weight of newborns. Results The indexes in the treatment group were higher than those in the control group. There was a significant difference between the two groups in the incidence of low birth weight and preterm birth rate (P <0.05). Conclusion The treatment of FGR with berberine is significant.